Current Challenges and Opportunities in Designing Protein-Protein Interaction Targeted Drugs.

ABSTRACT: It has been noticed that the efficiency of drug development has been decreasing in the past few decades. To overcome the situation, protein-protein interactions (PPIs) have been identified as new drug targets as early as 2000. PPIs are more abundant in human cells than single proteins and play numerous important roles in cellular processes including diseases. However, PPIs have very different physicochemical features from the conventional drug targets, which make targeting PPIs challenging. Therefore, as of now, only a small number of PPI inhibitors have been approved or progressed to a stage of clinical trial. In this article, we first overview previous works that analyzed differences between PPIs with PPI targeting ligands and conventional drugs with their binding pockets. Then, we const

SUBMITTER: Shin WH 

PROVIDER: S-EPMC7669531 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature